Other agents targeting mTOR in prostate cancer include the dual PI3K-mTOR inhibitor, BEZ235, which has shown potent in vitro radiosensitization both in normoxic and hypoxic conditions [173]. Here, MTOR is linked to Familial prostate cancer.